Clinical breast cancer最新文献

{"title":"Madarosis Among Breast Cancer Survivors: Correspondence","authors":"Hinpetch Daungsupawong , Viroj Wiwanitkit","doi":"10.1016/j.clbc.2024.11.004","DOIUrl":"10.1016/j.clbc.2024.11.004","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Page e210"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142766717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of Microinvasion in Breast Ductal Carcinoma in Situ Using Conventional Ultrasound Combined with Contrast-Enhanced Ultrasound Features: A Two-Center Study","authors":"Tingting Wu ,&nbsp;Jing Chen ,&nbsp;Sihui Shao ,&nbsp;Yu Du ,&nbsp;Fang Li ,&nbsp;Hui Liu ,&nbsp;Liping Sun ,&nbsp;Xuehong Diao ,&nbsp;Rong Wu","doi":"10.1016/j.clbc.2024.09.014","DOIUrl":"10.1016/j.clbc.2024.09.014","url":null,"abstract":"<div><h3>Background</h3><div>To develop and validate a model based on conventional ultrasound (CUS) and contrast-enhanced ultrasound (CEUS) features to preoperatively predict microinvasion in breast ductal carcinoma in situ (DCIS).</div></div><div><h3>Patients and Methods</h3><div>Data from 163 patients with DCIS who underwent CUS and CEUS from the internal hospital was retrospectively collected and randomly apportioned into training and internal validation sets in a ratio of 7:3. External validation set included 56 patients with DCIS from the external hospital. Univariate and multivariate logistic regression analysis were performed to determine the independent risk factors associated with microinvasion. These factors were used to develop predictive models. The performance was evaluated through calibration, discrimination, and clinical utility.</div></div><div><h3>Results</h3><div>Multivariate analysis indicated that centripetal enhancement direction (odds ratio [OR], 13.268; 95% confidence interval [CI], 3.687-47.746) and enhancement range enlarged on CEUS (OR, 4.876; 95% CI, 1.470-16.181), lesion size of ≥20 mm (OR, 3.265; 95% CI, 1.230-8.669) and calcification detected on CUS (OR, 5.174; 95% CI, 1.903-14.066) were independent risk factors associated with microinvasion. The nomogram incorporated the CUS and CEUS features achieved favorable discrimination (AUCs of 0.850, 0.848, and 0.879 for the training, internal and external validation datasets), with good calibration. The nomogram outperformed the CUS model and CEUS model (all <em>P</em> &lt; .05). Decision curve analysis confirmed that the predictive nomogram was clinically useful.</div></div><div><h3>Conclusion</h3><div>The nomogram based on CUS and CEUS features showed promising predictive value for the preoperative identification of microinvasion in patients with DCIS.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e178-e189"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP4/CARM1 Axis Promotes the Malignant Transformation of Breast Cancer Cells by Upregulating SLC7A11 Expression","authors":"Xin Li ,&nbsp;Changjiao Yan ,&nbsp;Jun Yun,&nbsp;Xin Xu,&nbsp;Hongliang Wei,&nbsp;Xiaolong Xu,&nbsp;Yike Li,&nbsp;Jun Yi","doi":"10.1016/j.clbc.2024.10.001","DOIUrl":"10.1016/j.clbc.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Coactivator associated arginine methyltransferase 1 (CARM1) has been identified as a regulator of breast cancer (BC) progression, yet the underlying mechanisms remain elusive.</div></div><div><h3>Methods</h3><div>Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess the mRNA expression of CARM1 and solute carrier family 7 member 11 (SLC7A11). Western blotting was conducted to detect the protein expressions of CARM1, ubiquitin specific peptidase 4 (USP4), and SLC7A11. Cell viability, apoptosis, invasion, and migration were evaluated using CCK-8 assay, flow cytometry, transwell assay, and wound-healing assay, respectively. Fe²⁺ and GSH levels were determined by colorimetric assay. Fluorescence microscopy and flow cytometry were utilized to quantify reactive oxygen species (ROS) production. Co-immunoprecipitation (Co-IP) assay and cycloheximide (CHX) assay were performed to investigate the relationship between USP4 and CARM1. Xenograft mouse model assay was conducted to validate the effects of USP4 silencing and CARM1 overexpression on the malignant phenotypes of BC cells.</div></div><div><h3>Results</h3><div>CARM1 and SLC7A11 expression was upregulated in BC tissues and cells when compared with normal breast tissues and cells. Silencing of CARM1 inhibited the malignant phenotypes of BC cells, including decreased cell viability, invasion, and migration and increased cell apoptosis, ferroptosis and oxidative stress. In addition, USP4 stabilized CARM1 protein expression through its deubiquitinating activity. Overexpression of CARM1 attenuated the effects of USP4 silencing in both MCF-7 and MDA-MB-231 cells. Furthermore, silencing of CARM1 reduced SLC7A11 expression, and SLC7A11 overexpression relieved the CARM1 silencing-induced effects. Further, overexpression of CARM1 counteracted the inhibitory effects of USP4 silencing on tumor growth <em>in vivo</em>.</div></div><div><h3>Conclusion</h3><div>Our study reveals a novel mechanism by which USP4-dependent CARM1 promotes the malignant growth of BC cells by interacting with SLC7A11. Targeting this axis may provide a potential therapeutic strategy for BC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e196-e207"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinical Review of Subcutaneous Trastuzumab and the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in the Treatment of HER2-Positive Breast Cancer","authors":"Julia L. Ziegengeist ,&nbsp;Antoinette R. Tan","doi":"10.1016/j.clbc.2024.10.005","DOIUrl":"10.1016/j.clbc.2024.10.005","url":null,"abstract":"<div><div>Therapy directed against human epidermal growth factor receptor type 2 (HER2) is the standard of care for patients with early-stage and metastatic HER2-positive breast cancer. Treating patients with HER2-positive breast cancer with anti-HER2-monoclonal antibodies, specifically trastuzumab and pertuzumab, is considered standard of care in the neoadjuvant and adjuvant settings and in the first-line setting for metastatic HER2-positive breast cancer. Pertuzumab and trastuzumab are commonly administered intravenously. Subcutaneous (SC) formulations of trastuzumab alone and as a combined product of pertuzumab and trastuzumab are now available for clinical use. Phase III trial results demonstrate that the efficacy and safety of SC trastuzumab and fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous (PH FDC SC) injection and the intravenous (IV) formulation counterparts are comparable. SC formulations of anti-HER2 monoclonal antibodies offer several advantages over IV counterparts, including shorter administration time, less need for IV access, and better resource utilization for treatment facilities. This review summarizes the clinical data supporting the use of SC trastuzumab and PH FDC SC injection in treating early-stage and metastatic HER2-positive breast cancer and highlights the benefits of SC injection compared to the IV formulations.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e124-e132"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142680996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Another Biosignature for Ductal Carcinoma In Situ—Have We Moved the Needle?","authors":"Hannah Bacon ,&nbsp;Ezra Hahn","doi":"10.1016/j.clbc.2024.10.017","DOIUrl":"10.1016/j.clbc.2024.10.017","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e208-e209"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Analysis of Breast Cancer Patients Qualifying for Adjuvant CDK4/6 Inhibitors","authors":"Yada Kanjanapan ,&nbsp;Wayne Anderson ,&nbsp;Mirka Smith ,&nbsp;Jenny Green ,&nbsp;Elizabeth Chalker ,&nbsp;Paul Craft","doi":"10.1016/j.clbc.2024.08.022","DOIUrl":"10.1016/j.clbc.2024.08.022","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant CDK4/6 inhibitors abemaciclib and ribociclib improved disease-free survival (DFS) added to endocrine therapy in hormone receptor (HR)-positive HER2-negative early breast cancer (EBC), in monarchE (<span><span>NCT03155997</span><svg><path></path></svg></span>) and NATALEE (<span><span>NCT03701334</span><svg><path></path></svg></span>) trials respectively. We assessed the proportion and outcome of EBC patients qualifying for adjuvant CDK4/6 inhibitors in the real-world.</div></div><div><h3>Methods</h3><div>Consecutive female patients with HR-positive HER2-negative EBC between 1997 and 2017 from the Australian Capital Territory and South-East New South Wales Breast Cancer Treatment Group registry were analyzed. Patients eligible for abemaciclib had ≥4 axillary nodes involved or 1-3 nodes plus primary &gt;5 cm or grade 3. Ribociclib eligibility was defined as node-positive and node-negative with primary &gt;5 cm or &gt;2 cm grade 3.</div></div><div><h3>Results</h3><div>Of 3840 patients, 671 (17.5%) were abemaciclib-eligible and 1587 (41.3%) ribociclib-eligible . The 5-year DFS was 77% and 94% in abemaciclib-eligible and noneligible registry patients respectively (HR 2.6, 95% CI 2.26-3.05, <em>P</em> &lt; .001). The 5-year DFS was 86% and 97% in ribociclib-eligible and noneligible registry patients respectively (HR 1.92, 95% CI 1.67-2.19, <em>P</em> &lt; .001). Compared with monarchE trial patients, abemaciclib-eligible registry patients were older (median 55 years in registry vs. 51 years in trial), with lower nodal burden (≥4 nodes in 44% in registry vs. 60% in trial). There were more stage III cancers in NATALEE trial patients (60%) than ribociclib-eligible registry patients (24%).</div></div><div><h3>Conclusions</h3><div>Many women with EBC will qualify for adjuvant CDK4/6 inhibitors (17.5% abemaciclib, 41.3% ribociclib) with resource and workforce implications. In the real-world setting, a greater proportion of adjuvant CDK4/6-eligible patients have lower stage disease, therefore the absolute benefit from treatment may be smaller than estimated by the trials.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e159-e169.e2"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of Digital Breast Tomosynthesis Versus Digital Mammography in Women With a Family History of Breast Cancer: A Systematic Review","authors":"Tong Li ,&nbsp;Jennifer Isautier ,&nbsp;Janie M. Lee ,&nbsp;M. Luke Marinovich ,&nbsp;Nehmat Houssami","doi":"10.1016/j.clbc.2024.09.013","DOIUrl":"10.1016/j.clbc.2024.09.013","url":null,"abstract":"<div><h3>Background</h3><div>There is limited evidence on the performance of digital breast tomosynthesis (DBT) in populations at increased risk of breast cancer. Our objective was to systematically review evidence on the performance of DBT versus digital mammography (DM) in women with a family history of breast cancer (FHBC).</div></div><div><h3>Methods</h3><div>We searched 5 databases (2011–January 2024) for studies comparing DBT and DM in women with a FHBC that reported any measure of cancer detection, recall, sensitivity and specificity. Findings were presented using a descriptive and narrative approach. Risk of bias was assessed using QUADAS-2/C.</div></div><div><h3>Results</h3><div>Five (4 screening, 1 diagnostic) studies were included (total 3089 DBT, 3024 DM) with most (4/5) being prospective including 1 RCT. All studies were assessed as being at high risk of bias or applicability concern. Four screening studies reported recall rate (range: DBT: 2.7%-4.5%, DM: 2.8%-11.5%) with 3 reporting DBT had lower rates than DM. Cancer detection rates (CDR) were reported in the same studies (DBT: 5.1-11.6 per 1000, DM: 3.8-8.3); 3 reported higher CDR for DBT (vs. DM), and 1 reported same CDR for both. Compared with DM, higher values for sensitivity, specificity and PPV for DBT were reported in 2 studies.</div></div><div><h3>Conclusion</h3><div>This review provides early evidence that DBT may outperform DM for screening women with a FHBC. Our findings support further evaluation of DBT in this population. However, summarized findings were based on few studies and participants, and high-quality studies with improved methodology are needed to address biases identified in our review.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e103-e112"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Early Breast Cancer Diagnosis With Contrast-Enhanced Ultrasound Radiomics: Insights From Intratumoral and Peritumoral Analysis","authors":"Guoqiu Li ,&nbsp;Xiaoli Huang ,&nbsp;Huaiyu Wu ,&nbsp;Hongtian Tian ,&nbsp;Zhibin Huang ,&nbsp;Mengyun Wang ,&nbsp;Qinghua Liu ,&nbsp;Jinfeng Xu ,&nbsp;Ligang Cui ,&nbsp;Fajin Dong","doi":"10.1016/j.clbc.2024.11.011","DOIUrl":"10.1016/j.clbc.2024.11.011","url":null,"abstract":"<div><h3>Introduction</h3><div>To develop and validate contrast-enhanced ultrasound (CEUS) radiomics model for the accurate diagnosis of breast cancer by integrating intratumoral and peritumoral regions.</div></div><div><h3>Materials and Methods</h3><div>This study enrolled 333 patients with breast lesions from Shenzhen people's hospital between March 2022 and March 2024. Radiomics features were extracted from both intratumoral and peritumoral (3 mm) regions on CEUS images. Significant features were identified using the Mann–Whitney U test, Spearman's correlation coefficient, and least absolute shrinkage and selection operator logistic regression. These features were used to construct radiomics models. The model's performance was evaluated using the area under the receiver operating characteristic curve, area under curve (AUC), decision curve analysis, and calibration curves.</div></div><div><h3>Results</h3><div>The radiomics models demonstrated robust diagnostic performance in both the training and testing sets. The model that combined intratumoral and peritumoral features showed superior predictive accuracy, with AUCs of 0.933 (95% CI: 0.891, 0.974) and 0.949 (95% CI: 0.916, 0.983), respectively, compared to the intratumoral model alone. Calibration curves indicated excellent agreement between predicted and observed outcomes, with Hosmer–Lemeshow test <em>P</em> = .97 and <em>P</em> <strong>=</strong> .62 for the both the training and testing sets, respectively. decision curve analysis revealed that the combined model provided significant clinical benefits across a wide range of threshold probabilities, outperforming the intratumoral model in both sets.</div></div><div><h3>Conclusion</h3><div>The radiomics model integrating intratumoral and peritumoral features shows significant potential for the accurate diagnosis of breast cancer, enhancing clinical decision-making and guiding treatment strategies.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages 180-191"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma-free Amino Acid Profile is Beneficial for Breast Cancer Screening in Women With Dense Breasts","authors":"Saeko Teraoka ,&nbsp;Hiroshi Yamamoto ,&nbsp;Shinya Kikuchi ,&nbsp;Yoshiya Horimoto ,&nbsp;Kimito Yamada ,&nbsp;Hiroshi Kaise ,&nbsp;Mari Hosonaga ,&nbsp;Takahiko Kawate ,&nbsp;Kana Miyahara ,&nbsp;Ai Ueda ,&nbsp;Mariko Asaoka ,&nbsp;Miki Okazaki ,&nbsp;Natsuki Uenaka ,&nbsp;Saori Kawai ,&nbsp;Takashi Ishikawa","doi":"10.1016/j.clbc.2024.11.001","DOIUrl":"10.1016/j.clbc.2024.11.001","url":null,"abstract":"<div><h3>Background</h3><div>AminoIndex™ Cancer Screening (AICS breast) was developed as a breast cancer screening test using multivariate analysis of plasma free amino acid (PFAA) profiles. This study investigated the relationship between the AICS breast rank and breast density on mammography (MMG) for the detection of breast cancer.</div></div><div><h3>Materials and Methods</h3><div>MMG and blood samples were obtained preoperatively from 224 patients with breast cancer who did not receive neoadjuvant chemotherapy between 2017 and 2019. PFAA concentration was measured using liquid chromatography-mass spectrometry, and the AICS breast and AICS ranks were calculated. Detection rates were compared between MMG (categories 3-5) and AICS breasts (ranks B and C) according to breast density.</div></div><div><h3>Results</h3><div>Breast density was classified as extremely dense in 9.4%, heterogeneously dense in 48.2%, scattered in 29.9%, and fatty in 12.5% of patients. Dense breasts (extremely dense and heterogeneously dense) represented 57.6%. The overall detection rate by MMG was 82.6% and significantly lower in patients with dense breasts (74.4%) compared to non-dense breasts (93.7%). The overall detection rate by AICS breast was 50.0%, with no difference between patients with dense breasts (45.7%) and those with non-dense breasts (55.8%). The combination of MMG and AICS breast increased the detection rate to 91.5% overall, 88.3% in patients with dense breasts, and 95.8% in those with non-dense breasts.</div></div><div><h3>Conclusion</h3><div>This study demonstrated that the detection rate of AICS breast was not associated with breast density, unlike MMG. Adding AICS breast to MMG may be beneficial for breast cancer screening in patients with dense breasts.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages 149-156"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy","authors":"Frank Vicini ,&nbsp;Chirag Shah ,&nbsp;Karuna Mittal ,&nbsp;Jame Abraham ,&nbsp;Megan Kruse ,&nbsp;Sheila Weinmann ,&nbsp;Michael Leo ,&nbsp;Rachel Rabinovitch ,&nbsp;Fredrik Wärnberg ,&nbsp;Pat W. Whitworth ,&nbsp;Brian J. Czerniecki ,&nbsp;Steven C. Shivers ,&nbsp;Troy Bremer","doi":"10.1016/j.clbc.2024.08.016","DOIUrl":"10.1016/j.clbc.2024.08.016","url":null,"abstract":"<div><h3>Purpose</h3><div>A subpopulation of women with ductal carcinoma in situ (DCIS) remains at risk for in-breast recurrence (IBR) following breast-conserving surgery (BCS) and radiation therapy (RT). The NSABP B-43 trial evaluated the role of concurrent RT and trastuzumab in patients with HER2-positive DCIS but did not reach the prespecified endpoint. We hypothesized that a 7-gene biosignature (DCISionRT) with its Residual Risk subtype (RRt) could identify 2 groups of HER2(3+) patients with significantly different IBR risks after BCS plus RT.</div></div><div><h3>Patients and Methods</h3><div>All patients with HER2(3+) DCIS (n = 178) treated with BCS plus RT were selected from a combined multinational patient cohort. Treatment decisions were neither randomized nor strictly rules-based. Biosignature testing was performed on all patients and stratified with previously defined groups: (1) Combined Low Risk group (DS ≤ 2.8) and Elevated Risk group (DS &gt; 2.8) without RRt or (2) Residual Risk subtype. Kaplan–Meier analysis was used to compute IBR curves.</div></div><div><h3>Results</h3><div>Sixty-three percent of HER2(3+) patients (113/178) were classified into the Residual Risk subtype. These patients had significantly higher 10-year rates of IBR compared to the nonresidual risk group (16.2% vs. 1.6%, <em>P</em> = .01). The Residual Risk subtype had more nuclear grade 3 disease (87% vs. 63%, <em>P</em> &lt; .001), but age, size, and grade were not associated with IBR rate (<em>P</em> = NS) on univariate and multivariable analysis. Only the Residual Risk group was associated with IBR (<em>P</em> = .05) in multivariate analysis.</div></div><div><h3>Conclusion</h3><div>The 7-gene biosignature with RRt identified a subset of HER2(3+) patients with greater IBR rates following BCS and RT beyond traditional clinical and pathologic features. Consideration of therapies to reduce these elevated IBR rates should be evaluated, including the incorporation of HER2-targeted therapy.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"25 2","pages":"Pages e152-e158.e1"},"PeriodicalIF":2.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}